Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer.

We propose a method for achieving an optimal protocol of intermittent androgen suppression for the treatment of prostate cancer. Since the model that reproduces the dynamical behavior of the surrogate tumor marker, prostate specific antigen, is piecewise linear, we can obtain an analytical solution for the model. Based on this, we derive conditions for either stopping or delaying recurrent disease. The solution also provides a design principle for the most favorable schedule of treatment that minimizes the rate of expansion of the malignant cell population.

[1]  P. Carroll,et al.  Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. , 2001, Urology.

[2]  Richard P. Hill,et al.  The Basic Science of Oncology , 1989 .

[3]  Gouhei Tanaka,et al.  A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer , 2008, J. Nonlinear Sci..

[4]  Gouhei Tanaka,et al.  Bifurcation analysis on a hybrid systems model of intermittent hormonal therapy for prostate cancer , 2008 .

[5]  M. Peyromaure,et al.  Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience. , 2005, Urology.

[6]  Gouhei Tanaka,et al.  Mathematical modelling of prostate cancer growth and its application to hormone therapy , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[7]  J. Cuzick,et al.  International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta‐analysis of 1446 patients , 2007, BJU international.

[8]  Nicholas Bruchovsky,et al.  Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer , 2006, Cancer.

[9]  N. Mottet,et al.  The role of intermittent androgen deprivation in prostate cancer , 2007, BJU international.

[10]  Kazuyuki Aihara,et al.  Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. , 2010, Journal of theoretical biology.

[11]  A. De la taille,et al.  Intermittent androgen suppression in patients with prostate cancer , 2003, BJU international.

[12]  Kazuyuki Aihara,et al.  Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[13]  L. Eapen,et al.  Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome. , 2007, International journal of radiation oncology, biology, physics.

[14]  R. Jennrich,et al.  Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. , 2007, Urology.

[15]  M. Gleave,et al.  Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. , 1995, Urology.

[16]  Kazuyuki Aihara,et al.  A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer. , 2008, Mathematical biosciences.

[17]  N. Sato,et al.  Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. , 2004, Urology.

[18]  S. Goldenberg,et al.  Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.